Daiichi Sankyo Records ¥354 Billion Valuation Loss From Price Drop In Ranbaxy Shares
This article was originally published in PharmAsia News
Daiichi Sankyo announced Jan. 5 a valuation loss of ¥354 billion for the fiscal quarter ending Dec. 31; the loss is associated with a more than 50 percent price drop in Ranbaxy shares the company acquired. With the loss, it is viewed that the company will report a loss in consolidated profit for the fiscal year ending March 31. Daiichi has previously estimated ¥65 billion in profit. It will be the first loss for the company since the merger of Daiichi and Sankyo in 2005. (Click here for more - Japanese language
You may also be interested in...
MUMBAI - Daiichi Sankyo, the majority equity holder in India's largest drug company Ranbaxy, has encountered a hurdle in its proposal to make an open offer for 20 percent shares in Zenotech Labs. Shareholders of Zenotech Labs have pleaded that the open offer price fixed by Daiichi Sankyo is far less than what Ranbaxy paid to acquire 46 percent of its equity a year ago
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.